Vericel Corp (VCEL) - Comprehensive Stock Analysis & Investment Research
Deep dive into Vericel Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Vericel Corp Investment Summary
When evaluating whether Vericel Corp (VCEL) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Vericel Corp (VCEL) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $2 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.
Financial Performance Analysis
Our comprehensive financial analysis covers Vericel Corp's revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Vericel Corp along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Vericel Corp is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Vericel Corp (Stock Symbol: VCEL) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Vericel Corp's leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Vericel Corp...
Sector & Industry Analysis
In-depth sector dynamics and industry context for Vericel Corp...
Revenue & Growth Analysis
Vericel Corp generates annual revenues of $306 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Vericel Corp...
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Vericel Corp...
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Vericel Corp...
Strategic Market Position
Vericel Corp strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.
Industry Competitive Landscape
Vericel Corp competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company shows positive operational efficiency through free cash flow generation of $62 million annually , with year-over-year cash flow growth of 47.5%. Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.
Margin & Pricing Power Analysis
The company maintains a 74.5% gross margin which reflects strong pricing power and/or low direct production costs relative to revenue. Gross margins are only comparable within an industry, so read this level against the company's peers rather than the market as a whole.
Operating margin of 6.0% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.
Asset Utilization Efficiency
Asset turnover ratio of 0.61x indicates moderate asset turnover. Lower turnover is expected where the business model requires significant infrastructure, so the ratio should be read against the company's own industry.
Financial Strength & Leverage
Current ratio of 5.04 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.